首页> BMC palliative care> Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo controlled, randomised clinical trial of efficacy and safety of cannabidiol (CBD).

Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo controlled, randomised clinical trial of efficacy and safety of cannabidiol (CBD).

导出 OA

翻译打印收藏纠错

第一作者： Phillip,Good

第一单位： Mater Health Services, Mater Research Institute-University of Queensland, St Vincent's Private Hospital Brisbane, Brisbane, Qld, Australia. Phillip.Good@mater.org.au.

作者： Phillip,Good ^[1] ; Alison,Haywood ^[2] ; Gauri,Gogna ^[3] ; Jennifer,Martin ^[4] ; Patsy,Yates ^[5] ; Ristan,Greer ^[6] ; Janet,Hardy ^[7]

作者单位： Mater Health Services, Mater Research Institute-University of Queensland, St Vincent's Private Hospital Brisbane, Brisbane, Qld, Australia. Phillip.Good@mater.org.au. ^[1] School of Pharmacy and Pharmacology, Menzies Health Institute Queensland, Griffith University, Gold Coast, Australia.;Mater Research Institute - The University of Queensland, Brisbane, Australia. ^[2] Greenslopes Private Hospital, Gold Coast Health Service, Greenslopes, Australia. ^[3] The Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE), New Lambton Heights, Australia.;Discipline of Clinical Pharmacology, School of Medicine and Public Health, University of Newcastle, Callaghan, Australia. ^[4] School of Nursing, Queensland University of Technology, Victoria Park Rd, Kelvin Grove, QLD, 4059, Australia.;Centre for Palliative Care Research and Education, Queensland Health, Brisbane, Australia. ^[5] Torus Research, Mater Research Institute-University of Queensland, QLD, St Lucia, Australia. ^[6] Mater Health Services, Mater Research Institute-University of Queensland, Brisbane, Queensland, Australia. ^[7]

关键词 Cancer Cannabidiol Cannabis Palliative care RCT Symptom control